Tag: <span>Ovarian Cancer</span>

Home / Ovarian Cancer
Researchers use ultrasound to predict ovarian cancer
Post

Researchers use ultrasound to predict ovarian cancer

RADIOLOGICAL SOCIETY OF NORTH AMERICA IMAGE: REPRESENTATIVE TRANSVAGINAL US IMAGES OF CLASSIC LESIONS; COLOR DOPPLER BLOOD FLOW WITH COLOR BAR SIGNIFIES DIRECTION OF FLOW. (A) TRANSVERSE COLOR DOPPLER IMAGE OF RIGHT ADNEXA DEPICTS AN ANECHOIC CYST WITH NO INTERNAL ELEMENTS OR DOPPLER FLOW, COMPATIBLE WITH A SIMPLE CYST. (B) TRANSVERSE COLOR DOPPLER IMAGE OF LEFT...

Research shows new drug combination effective for patients with advanced ovarian cancer
Post

Research shows new drug combination effective for patients with advanced ovarian cancer

by Yale University Credit: Unsplash/CC0 Public Domain A new study led by researchers at Yale Cancer Center and the University of Maryland Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data shows it also may significantly extend both...

Post

Earlier ovarian cancer detection with a pilot version of “itty bitty” device

Biomedical engineering professor and BIO5 Institute Director Jennifer Barton has spent nearly a decade developing a falloposcope for ovarian cancer detection in its early stages. Banner – University Medical Center surgeon Dr. John Heusinkveld has now used the device to capture images of study participants’ fallopian tubes for the first time. Due to a lack of effective...

Post

Ovarian cancer is not a silent killer

The myth that ovarian cancer is a “silent killer” is just that, a myth, says a UW Medicine expert on the subject. The more clinicians and primary-care providers recognize the early signs, instead of “blowing them off” as just gastrointestinal problems or nerves, the more lives will be saved, said Dr. Barbara Goff, professor and chair of obstetrics and...

Ovarian cancer researchers bring natural product β-escin to the fore
Post

Ovarian cancer researchers bring natural product β-escin to the fore

by University of Chicago Medical Center Credit: Unsplash/CC0 Public Domain For women with ovarian cancer, there is a high rate of mortality, in part due to the ease of cancer cell spreading, or metastasis, in the abdominal cavity. Current treatments can be expensive and have proven to be ineffective against long-term survival in these patients....

Assay for patient-specific monitoring and treatment for ovarian cancer
Post

Assay for patient-specific monitoring and treatment for ovarian cancer

by  KU Leuven Figure 1. Interrogation of the tumor derived bulk-RNAseq or tumor/blood single-cell (sc)-RNAseq data of patients with cancer. (A,B) The t-distributed stochastic neighbor embedding (tSNE) visualizations of indicated immune cell types, from scRNAseq data from patients with renal cell and large cell neuroendocrine carcinoma (n=4 patients in total) (derived from GSE139555) isolated from tumor...

A potential therapeutic target and biomarker for ovarian cancer
Post

A potential therapeutic target and biomarker for ovarian cancer

by  Medical College of Wisconsin Ovary. Credit: Public Domain Scientists at the Medical College of Wisconsin (MCW) Cancer Center and an international team of collaborators have identified a new mechanism of cMYC regulation in ovarian cancer. Although the cMYC gene aberration is present in nearly half of all cancer patients, it’s been a challenge to use cMYC as a therapeutic target due to its ‘undruggable’ protein structure. The study...

New approach to improve ovarian cancer treatment
Post

New approach to improve ovarian cancer treatment

by  University of Pittsburgh Microscopic images of mouse ovarian cancers treated with an immune checkpoint inhibitor drug. When cancer-associated mesenchymal stem cells are absent (left), immune cells (shown in red) are found throughout the tumor, but when cancer-associated mesenchymal stem cells are present (right), they create a barrier that traps immune cells at the border of...

Anti-cancer inhibitor could have dual effect
Post

Anti-cancer inhibitor could have dual effect

by Will Doss,  Northwestern University Figure 1. Tissue transglutaminase (TG2) promotes peritoneal tumor growth in a syngeneic ovarian cancer (OC) mouse model by preventing CD8+ T cell infiltration into ascites. (A, B) Volume of peritoneal ascites (mean±SEM, n=23 per group, cumulative data from four independent experiments are shown) (A), and numbers of cells in ascites (mean±SEM,...

Immune system link with rare ovarian cancer could guide future treatment
Post

Immune system link with rare ovarian cancer could guide future treatment

by  Institute of Cancer Research Credit: Jan Chlebik, ICR Immune-related genes are associated with the development of the rare cancer ovarian clear cell carcinoma (OCCC), new research has found. A new study led by researchers at the Institute of Cancer Research, London, investigated the immune characteristics of OCCC and uncovered gene alterations linked to poor prognosis for the disease. It also identified specific immune cells that...